In this case report,a patient with voriconazole-induced periostitis exhibits classic symptoms&elevatedALPlevels, which quicklyresolvefollowingthediscontinuationofvoriconazole.
Donald Thomas, MD, FACP, FACR, RhMSUS, & Jason Liebowitz, MD |
“ANA’s are some of most commonly ordered tests but what exactly are they and what do you do with a positive ANA? Check out the Editor’s Pick for October to learn more,” says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS.
With more than 350 research abstracts on systemic lupus erythematosus, lupus nephritis and related conditions accepted for presentation at ACR Convergence 2024, we’re happy to announce that Graciela S. Alarcón, MD, MPH, has accepted the monumental task of reviewing the abstracts and identifying those most likely to make a difference to clinical practice or lead…
Ethical conduct is the cornerstone of any professional organization, particularly when its decisions have an impact on public health. The ACR recognizes the importance of upholding ethical standards and has established a Code of Ethics to guide its members. Here we explore the practical application of the ACR’s Code of Ethics.1 Manage Potential Conflicts Central…
Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.
Most Sunday mornings, I make myself an exceptional cup of pour-over coffee and sit down on my deck with the latest issue of the New England Journal of Medicine. I check out the image of the week. I read the case report with pen in hand, racing to diagnose the patient before the authors spill…
As uncertainty persists around federal policies regarding copay accumulator programs, a growing number of states are stepping in. A total of 21 states have banned the programs and others are increasing transparency requirements